ALUMIS INC.
Close on Oct 19, 2026
- Market cap
- $809.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Alumis
Pharmaceutical Preparations, SIC 2834
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oral therapies to replace broad immunosuppression for patients with immune-mediated conditions. The company's lead product candidate is envudeucitinib, an allosteric Tyrosine Kinase 2 (TYK2) inhibitor being evaluated for plaque psoriasis and systemic lupus erythematosus. Its pipeline also includes A-005, a central nervous system-penetrant TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative disorders, alongside lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease acquired via its merger with ACELYRIN.
The company operates without internal manufacturing facilities, outsourcing clinical-stage production and supply of active pharmaceutical ingredients and raw materials to third-party contract manufacturers located internationally, including in India and Taiwan. Its clinical trials and patent protections span across the United States, Europe, the United Kingdom, Latin America, and Asia-Pacific countries. The provided text does not disclose the specific location of its corporate headquarters.
Summary of the business section of Alumis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ALUMIS INC.
- Founded
- 2021
- Headquarters
- South San Francisco, CA
- Address
- 280 East Grand Avenue 94080
- Phone
- (650) 231-6625
- Employees
- 170, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- ALMS
- Exchange
- Nasdaq
- IPO date
- Jun 28, 2024
- Shares outstanding
- 129M, Aug 6, 2026
- Public float
- $183.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1847367
- CUSIP
- 022307102
- ISIN
- US0223071020
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin Babler | President, CEO and Chairman, Director | 109,454 |
| Sanam Pangali | Chief Legal Officer | 9,747 |
| Mark Christopher Bradley | Chief Development Officer | 68,559 |
| John R. Schroer | Chief Financial Officer | 24,718 |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 214,163 |
| David M. Goldstein | Chief Scientific Officer | 248,201 |
| Jorn Drappa | Chief Medical Officer | 56,892 |
| Derrick Richardson | SVP, People and Culture | 42,800 |
| Sara Klein | Chief Legal Officer | 33,796 |
| Srinivas Akkaraju | Director | 6,966,072 |
| Patrick Machado | Director | 10,617 |
| Lynn A. Tetrault | Director | 3,553 |
| Sapna Srivastava | Director | 3,553 |
| Zhengbin Yao | Director | 27,082 |
| James B. Tananbaum | Director | 1,123,337 |
| David E. Goel | Director | 10,645,966 |
| AyurMaya Capital Management Company, LP | Director | 15,139,707 |
| Alan Colowick | Director | 18,404 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 21, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 21, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 27, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 28, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 25, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 19, 2021 | Name change | Name changed from FL2021-001, Inc. to ALUMIS INC. |